Kim Ferguson Email & Phone Number

Boulder, Colorado, United States

--Managed planning and execution of clinical development activities for novel T Regulatory cell stimulator NKTR-358 in collaboration with partner Eli Lilly, including timelines, project plans, and team meetings. --Managed collaborations for evaluation of NKTR-214, a novel cancer immunotherapy candidate, to test in clinical studies in combination with cancer therapeutics from other companies. --Managed Research pipeline and worked with the Chief Scientific Officer and Research Executive staff to coordinate project planning, resource management and budget preparation for a team of ~60 scientists and support staff over 3 separate sites.

South San Francisco, Ca

• Prepared agenda and minutes, and followed up on actions for bi-weekly Executive team staff meetings• Prepared cross-functional updates, timelines and project summaries for quarterly Board of Directors meetings• Ensured regular updates in key areas of development, commercial, legal and finance functions delivered to CEO and executive team to keep high priority goals on track • Served as Alliance Manager for cobimetinib, an Exelixis-discovered compound in late stage clinical development by Roche/Genentech, coordinating joint meetings and facilitating follow-up on Exelixis contribution to development and commercial activities• Managed development of cabozantinib presentations for medical meetings and manuscript submissions

South San Francisco, Ca

• Oversaw cabozantinib program deliverables, prepared agendas and minutes for Phase 1-3 clinical study project teams to ensure timelines remained on track• Coordinated preparation of NDA sections for cabozantinib in medullary thyroid cancer, contributing to on schedule filing and approval in November 2012• Coordinated reviews of clinical documents by development team senior staff to ensure their timely completion and submission • Managed development of cabozantinib publications with internal teams, senior management, and clinical investigators, resulting in numerous presentations for major medical meetings such as ASCO• Managed Promotional Review Committee to ensure COMETRIQTM promotional materials for medullary thyroid cancer were reviewed and approved in timely fashion for submission to regulatory agencies• Coordinated Distribution and Access sub-team with internal commercial and manufacturing teams to ensure the supply chain for cabozantinib was robust and prepared to meet demand • Performed clinical data reviews for Phase 1-2 cabozantinib studies in several cancer indications and contributed to data preparation for medical meeting presentations and publication

South San Francisco, Ca

• Facilitated interactions with project team internally and with BMS to ensure timelines were met and deliverables were sent to BMS for three Phase 1/1b programs --Coordinated preparation for joint meetings, prepared minutes, ensured action items were captured and appropriate follow-up occurred --Facilitated resolution of disagreements regarding strategic execution of these programs --Ensured effective communication of regulatory documents and other items of importance to BMS --Provided updates and program summaries to senior management at Exelixis• Managed XL184 co-development with BMS through coordination of Exelixis internal project team activities and facilitation of joint meetings --Coordinated collaboration meetings and prepared minutes to ensure joint timelines, goals and deliverables were achieved --Collaborated with BMS publications manager to jointly manage preparation of publications, including presentations for meetings, booth materials, and manuscripts --Ensured documents were transferred to appropriate BMS sub-teams and communicated BMS feedback to Exelixis management team --Worked with BMS alliance manager to track progress towards goals and resolve areas of misalignment

South San Francisco, Ca

• Managed multidisciplinary XL413 development project team internally and with BMS to ensure IND-enabling activities completed and key documents provided to BMS on schedule --Established timelines and oversaw preparation, review and delivery of IND Sections 7 and 8 --Led to BMS filing of the IND and initiation of a Phase 1 trial --Facilitated joint conference calls with BMS and prepared minutes, including CMC, Non-clinical toxicology, and Preclinical sub-team meetings --Prepared presentations for monthly senior management program review • Managed multidisciplinary XL844 internal program, facilitating project team interactions to ensure timely continuation of Phase 1 activities, meeting goal of pancreatic cancer go/no-go decision --Coordinated internal project team meetings; prepared agendas and minutes --Managed reviews and timelines for preparation of key program documents and deliverables such as the Investigator’s Brochure update and IND annual report --Prepared presentations for monthly senior management review of the program

South San Francisco, Ca

• Managed multidisciplinary scientific teams working on target identification /validation and lead validation/ optimization projects for internal oncology pipeline and collaboration with BMS• Resulted in advancement of drug candidates through the Exelixis Discovery pipeline, including one into Phase 1 clinical trials• Resulted in successful validation and HTS readiness of 5 oncology targets selected by either Exelixis or BMS for further development and 3MM$ in milestone payments

South San Francisco, Ca

• Managed and executed cell-based assay development and target validation for internal oncology projects• Resulting data contributed to prioritization of targets in the Exelixis pipeline

South San Francisco, Ca

• Involved in planning, management and execution of Metabolic Disease Program using invertebrate models• Resulted in partnership with Pharmacia Corp. and delivery of 10 novel candidate therapeutic targets for Metabolic Syndrome• Generated >$1MM in milestone payments

Ph.D., Molecular Biology

B.S., Molecular Biology